Muscling in: Gene therapies for muscular dystrophy target RNA
Author(s) -
Joel R. Chamberlain,
Jeffrey S. Chamberlain
Publication year - 2010
Publication title -
nature medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.536
H-Index - 547
eISSN - 1546-170X
pISSN - 1078-8956
DOI - 10.1038/nm0210-170
Subject(s) - muscular dystrophy , myotonic dystrophy , medicine , rhabdomyosarcoma , genetic enhancement , duchenne muscular dystrophy , alveolar rhabdomyosarcoma , bench to bedside , dystrophin , antisense therapy , gene , bioinformatics , cancer research , pathology , biology , genetics , rna , sarcoma , locked nucleic acid , medical physics
Muscle diseases can take many forms, from the progressive muscle degeneration of dystrophies to the childhood cancer rhabdomyosarcoma. In 'Bench to Bedside', Joel R. Chamberlain and Jeffrey S. Chamberlain discuss studies using antisense oligonucleotides to treat Duchenne muscular dystrophy and myotonic dystrophy. In 'Bedside to Bench', Simone Hettmer and Amy J. Wagers examine the implications of clinical studies describing a type of rhabdomyosarcoma that resembles acute leukemia. The findings dovetail with other studies suggesting that some of these cancers might originate outside of muscle tissue and highlight the need for a better understanding of the cells that give rise to this condition.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom